



Attorney Docket No.: 5739.200-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Weibel et al.

Serial No.: 09/450,609

Group Art Unit: 1614

Filed: November 30, 1999

Examiner: J. Kim

Confirmation No: 7926

For: New Pharmaceutical Composition And The Process For Its Preparation

AMENDMENT FEE TRANSMITTAL

Commissioner for Patents  
Washington, DC 20231

Sir:

Transmitted herewith is an Amendment for the above-identified application in response to the Office Action mailed 22 November 2000.

It is respectfully requested that the time for response to the Office Action dated 22 November 2000 be extended for a period of 2 months from 22 February 2001 to 22 April 2001. The required fee for the extension is estimated to be \$390.

No additional claims fee is required. Please charge the required extension fee, estimated to be \$390, to Novo Nordisk of North America, Inc., Deposit Account No. 14-1447.

A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: 20 April 2001

*Valeta A. Gregg*  
Valeta A. Gregg, Reg. No. 35,127  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123

04/25/2001 HBERHE 00000016 141447 09450609

FC:116 390.00 CH



23650

PATENT TRADEMARK OFFICE

#12  
BD  
RECEIVED  
APR 26 2001  
TECH CENTER 1600/2900  
4-2nd